<DOC>
	<DOCNO>NCT02064426</DOCNO>
	<brief_summary>Evaluate efficacy safety 36 month titrate dose treatment BAY85-3934 versus epoetin alfa/beta . Titration base subject 's hemoglobin ( Hb ) response tolerability prior dose . Planned dos include 15 , 25 , 50 , 75 , 100 , 150 mg daily .</brief_summary>
	<brief_title>Long Term Extension Study Maintenance Treatment Anemia Associated With Chronic Kidney Disease ( CKD ) Hemodialysis Subjects Epoetin Alfa / Beta Treatment Versus BAY85-3934</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Eligible male female subject previously enrol Study 16208 , diagnosis anemia associate CKD , hemodialysis . Men agree use adequate contraception sexually active woman without childbearing potential Participation completion treatment Study 16208 ; subject must receive 16 week study medication complete end treatment visit ( Day 113 ) parent study Mean Hb concentration 9.5 11.5 g/dL , inclusive , evaluation period ( i.e. , last 4 week parent study ) subject complete 16 week treatment BAY853934 , epoetin alfa , epoetin beta Study 16208 A schedule kidney transplant organ transplant within next 6 month ( wait list exclude subject ) Updates medical surgical history meet exclusion criterion parent study Subjects treat immunosuppressive therapy breast cancer resistant protein ( BCRP ) substrates , irinotecan , topotecan , methotrexate , imatinib , lapatinib Sustained , poorly control arterial hypertension hypotension baseline , define mean BP â‰¥ 180/110 mmHg systolic BP &lt; 95 mmHg , respectively Severe rhythm conduction disorder ( e.g. , HR &lt; 50 &gt; 110 bpm , atrial fibrillation flutter , prolong QT &gt; 500 msec , second third degree atrioventricular [ AV ] block ) New York Heart Association Class III IV congestive heart failure Severe hepatic insufficiency ( defined alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gammaglutamyl transferase &gt; 3 x upper limit norma [ ULN ] , total bilirubin &gt; 2 mg/dL , ChildPugh B C ) active hepatitis investigator 's opinion An ongoing SAE Study 16208 assess related study drug Alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Anemia CKD dialysis</keyword>
</DOC>